Taiho, Cullen partner to develop TAS6417

Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) granted Cullen Pearl exclusive, worldwide rights excluding Japan to develop and commercialize cancer candidate TAS6417. Taiho will receive an upfront payment and be eligible for regulatory and sales milestones, plus royalties. The company said details are not disclosed.

Taiho's strategic corporate venture arm, Taiho Ventures LLC, and Cullinan Oncology will provide funding for Cullinan Pearl’s series A round...